Takiyama Yumi

タキヤマユミ | Takiyama Yumi

Affiliation and department：

Research field (1)： Metabolism and endocrinology

Research keywords (1)： Diabetic Kidney Disease

Research theme for competitive and other funds (3)：

2022 - 2025 Diabetic Circulatory Disorder
2019 - 2022 Fetal overnutrition induced fast progression of diabetic kidney disease
2015 - 2018 Metallothionein 3: A New Player in Diabetic Nephropathy

Papers (22)：

Ryoichi Bessho, Yumi Takiyama, Takao Takiyama, Hiroya Kitsunai, Yasutaka Takeda, Hidemitsu Sakagami, Tsuguhito Ota. Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Scientific reports. 2019. 9. 1. 14754-14754
Yumi Takiyama, Yumi Takiyama'Correspondence information aboutYumi Takiyama, Toshihiro Sera, Masanori Nakamura, Kanaki Ishizeki, Yasuaki Saijo, Tsuyoshi Yanagimachi, Manami Maeda, Ryoichi Bessho, Takao Takiyama, et al. Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8. EBioMedicine. 2018. 36. 329-346
Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, et al. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects. MOLECULAR METABOLISM. 2017. 6. 2. 226-231
Kuralay Atageldiyeva, Yukihiro Fujita, Tsuyoshi Yanagimachi, Katsutoshi Mizumoto, Yasutaka Takeda, Jun Honjo, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Masakazu Haneda. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice. PLOS ONE. 2016. 11. 6. e0157672.
Yukihiro Fujita, Tsuyoshi Yanagimachi, Yasutaka Takeda, Jun Honjo, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Masakazu Haneda. Alternative form of glucose-dependent insulinotropic polypepide and its physiology. JOURNAL OF DIABETES INVESTIGATION. 2016. 7. 33-37

ｍore...

MISC (12)：

Takao Takiyama, Ryoichi Bessho, Kazuki Sawamoto, Yumi Takiyama. Maternal Overnutrition Causes DNA Alkylation in Fetal Liver, Suppresses FasL, and Upregulates HIF-1 Signaling Pathway in Neonatal Liver in Nonalcoholic Steatohepatitis (NASH)-Based Hepatocellular Carcinoma in Offspring. DIABETES. 2020. 69
Ryoichi Bessho, Yumi Takiyama, Manami Maeda, Kuralay K. Atageldiyeva, Yukihiro Fujita, Masakazu Haneda. Zinc; HIF-1 Mimetic in Human Renal Proximal Tubular Cells. DIABETES. 2016. 65. A137-A137
Yumi Takiyama, Manami Maeda, Kuralay K. Atageldiyeva, Tsuyoshi Yanagimachi, Jun Honjo, Yukihiro Fujita, Atsuko Abiko, Masakazu Haneda. A New Player in Diabetic Nephropathy: Metallothionein 3 Is a Target for Hypoxia Inducible Factor-1. DIABETES. 2015. 64. A142-A142
Y. Takiyama, M. Maeda, K. K. Atageldiyeva, T. Yanagimachi, J. Honjo, Y. Fujita, Y. Makino, M. Haneda. Zinc exerts anti-fibrotic action by inhibiting TGF-beta1-induced type I collagen and fibronectin in human renal proximal tubular cells. DIABETOLOGIA. 2014. 57. S480-S480
Yumi Takiyama, Ryoichi Bessho, Manami Maeda, Kuralay K. Atageldiyeva, Tsuyoshi Yanagimachi, Jun Honjo, Yukihiro Fujita, Yuichi Makino, Masakazu Haneda. SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes. DIABETES. 2014. 63. A136-A136

ｍore...

Professional career (1)：

医学博士 (旭川医科大学)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page